Disc Medicine's DISC-3405 Shows Promising Phase 2 Results in Polycythemia Vera Trial — Disc Medicine, Inc.

Event summary

Disc Medicine presented initial Phase 2 trial results for DISC-3405 in polycythemia vera (PV) patients at the SOHO annual meeting, showing increased hepcidin and lowered serum iron.
DISC-3405 reduced phlebotomy events by 85% in Cohort A participants, with 61.5% remaining phlebotomy-free through 26 weeks.
The trial enrolled 40 adult participants with PV, with Cohort A showing controlled hematocrit and improved symptom burden.
Disc also presented positive results from the Phase 2 RALLY-MF trial of selcodebart (DISC-0974) in myelofibrosis patients.
The company plans to provide an update on RESTORE-PV and initial data from the Phase 1b trial of DISC-3405 in sickle cell disease by the end of 2026.

The big picture

Disc Medicine's positive Phase 2 results for DISC-3405 in polycythemia vera patients highlight the potential of iron restriction as a transformative treatment approach. The data supports the company's commitment to hematologic oncology and positions DISC-3405 as a promising candidate for addressing the unmet needs of PV patients. With two programs advancing toward potential pivotal development in myeloproliferative neoplasms, Disc Medicine is strengthening its position in the competitive biopharmaceutical landscape.

What we're watching

Clinical Progression: Whether DISC-3405 can sustain its efficacy and safety profile in larger, more diverse patient populations.
Regulatory Pathway: The pace at which Disc Medicine advances DISC-3405 toward potential pivotal development in myeloproliferative neoplasms.
Pipeline Expansion: How the initial data from the Phase 1b trial of DISC-3405 in sickle cell disease will impact the company's strategic focus.